Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEFZIL vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Pharyngitis/tonsillitis (Streptococcus pyogenes),Otitis media (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis),Acute sinusitis,Acute bacterial exacerbation of chronic bronchitis,Skin and skin structure infections (uncomplicated)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Cefprozil is not extensively metabolized; approximately 60% of the dose is excreted unchanged in the urine. Renal excretion via tubular secretion and glomerular filtration.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
65-80% bound to plasma proteins (mainly albumin)
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.23-0.35 L/kg; distributes well into body fluids and tissues including skin, soft tissue, and respiratory tract
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 90-95%
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Cr Cl 30-49 m L/min: 250 mg twice daily; Cr Cl 10-29 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
6 months to 12 years: 30 mg/kg/day divided twice daily (max 1 g/day); for pharyngitis/tonsillitis: 20 mg/kg/day divided twice daily (max 500 mg/day).
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Adjust dose based on renal function; no specific geriatric dose adjustments other than renal considerations.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
None.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hypersensitivity reactions (including anaphylaxis) in penicillin-allergic patients,Clostridium difficile-associated diarrhea (CDAD),Seizures with high doses or renal impairment,Hemolytic anemia (rare),Prolonged prothrombin time (rare)
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to cefprozil or other cephalosporins,Immediate-type hypersensitivity to penicillins (cross-reactivity risk)
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No clinically significant food interactions. High-fat meals may slightly delay absorption but do not affect overall absorption extent. Avoid alcohol during therapy as it may increase risk of disulfiram-like reaction (rare with cephalosporins).
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies. Risk cannot be ruled out. First trimester: No reported teratogenicity in animal studies; clinical data insufficient. Second/third trimester: No known risk; use only if clearly needed.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Cefprozil (CEFZIL) is excreted in human milk in low amounts. Milk-to-plasma ratio is approximately 0.3. Considered compatible with breastfeeding; however, monitor infant for potential gastrointestinal effects.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No dose adjustment routinely required. Physiologic changes in pregnancy (increased renal clearance, volume of distribution) may require higher doses for severe infections, but data insufficient to recommend specific adjustments. Use standard adult dosing unless renal impairment.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
CEFZIL (cefprozil) is a second-generation cephalosporin with activity against Gram-positive cocci (including Streptococcus pyogenes, Streptococcus pneumoniae, and methicillin-susceptible Staphylococcus aureus) and some Gram-negative bacteria (Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli). It has a longer half-life (1.3 hours) compared to cephalexin, allowing twice-daily dosing. It is FDA-approved for acute sinusitis, pharyngitis/tonsillitis, otitis media, acute bacterial exacerbation of chronic bronchitis, secondary bacterial infection of acute bronchitis, and uncomplicated skin and skin structure infections. Note that it is not reliable against penicillin-resistant S. pneumoniae or beta-lactamase-producing H. influenzae (though it is more stable than first-generation agents). In penicillin-allergic patients, cross-reactivity risk is low but not zero (avoid if immediate-type hypersensitivity to penicillin). Dose adjustment required for creatinine clearance <30 m L/min: give standard dose every 12 hours for first dose, then 50% of standard dose every 12 hours. Available as 250 mg and 500 mg tablets and as an oral suspension (125 mg/5 m L or 250 mg/5 m L). Refrigerate suspension after reconstitution; discard after 14 days.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take this medication exactly as prescribed by your doctor, usually every 12 hours.,You may take this medication with or without food; however, taking with food may help reduce stomach upset.,Complete the full course of therapy, even if you feel better, to reduce the risk of antibiotic resistance.,Shake the oral suspension well before each dose. Use a proper measuring spoon or dosing syringe to ensure accurate dose.,Store the oral suspension in the refrigerator (not freezer) and discard any unused portion after 14 days.,Notify your doctor if you develop diarrhea, especially if it is watery or bloody; do not use anti-diarrhea medications without consulting your doctor.,Seek immediate medical attention if you experience signs of an allergic reaction: rash, hives, itching, difficulty breathing, tightness in chest, swelling of face/mouth/tongue.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEFZIL vs ALFENTA, answered by our medical review team.
CEFZIL is a Cephalosporin Antibiotic that works by Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEFZIL and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEFZIL is: 500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEFZIL and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEFZIL is classified as Category C. FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies. Risk cannot be ruled out. First trimester: No reported teratogenicity in a. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.